Martinez‐Mier 2006.

Methods	Design: open‐label RCT Duration: May 2004 to January 2005 Follow up: 12 months
Participants	Setting: single centre Country: Mexico Kidney transplant recipients: all LD Number (group 1/group 2): 41 (20/21) Mean age ± SD (years): group 1 (29.6 ± 7.6); group 2 (31.2 ± 9.21) Sex (M/F): group 1 (12/8); group 2 (12/9) Exclusions: evidence of systemic infection; HLA identical donor; prior treatment for cancer; pregnancy; weight > 105 kg; hypersensitivity to macrolide antibiotics; total cholesterol > 300 mg/dL; triglycerides > 400 mg/dL; WBC < 3000/mm3, or platelets < 75,000/mm3
Interventions	Treatment group 1 SRL: 10 mg single dose then 3 mg/m2 for levels 10 to 15 ng/mL for 3 months and then 5 to 10 ng/mL Treatment group 2 CSA: 4 to 8 mg/kg for levels 150 to 300 ng/mL for 6 months and then 100 to 200 ng/mL Co‐interventions MMF: dose 2g/d Basiliximab: 20 mg intraoperatively and at day 4 MP: 1g IV intraoperatively Prednisolone: initial dose 20 mg; 5 mg at 6 months
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with a functioning graft Acute rejection CrCl SCr CAN Infection CMV Surgical adverse effects Haematological adverse effects Biochemical adverse effects Cosmetic/lifestyle adverse effects
Notes	Comparison: TOR‐I versus CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes laboratory based and unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for
Selective reporting (reporting bias)	Low risk	All prespecified outcomes mentioned
Other bias	Unclear risk	Insufficient information to permit judgement